Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function

Journal of Virology

Volumn 85, Issue 20, 2011, Pages 10785-10797

  Eggink, Dirk ^a,d   Bontjer, Ilja ^a   Langedijk, Johannes P M ^b   Berkhout, Ben ^a   Sanders, Rogier W ^a,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Pepscan Systems   (Netherlands)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; T 2635; TIFUVIRTIDE; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; MEMBRANE FUSION; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS REPLICATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; MUTATION, MISSENSE; PEPTIDES; SELECTION, GENETIC; SERIAL PASSAGE; VIRULENCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80055013474     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05331-11     Document Type: Article

References (73)

1. Abrahamyan, L. G., R. M. Markosyan, J. P. Moore, F. S. Cohen, and G. B. Melikyan. 2003. Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion. J. Virol. 77:5829-5836.
2. Anastassopoulou, C. G., et al. 2011. Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology 413:47-59.
3. Anastassopoulou, C. G., T. J. Ketas, P. J. Klasse, and J. P. Moore. 2009. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A. 106:5318-5323.
4. Aquaro, S., et al. 2006. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J. Antimicrob. Chemother. 58:714-722.
5. Baldwin, C., and B. Berkhout. 2007. HIV-1 drug-resistance and drug-dependence. Retrovirology 4:78.
6. Baldwin, C., and B. Berkhout. 2008. Mechanistic studies of a T20-dependent human immunodeficiency virus type 1 variant. J. Virol. 82:7735-7740.
7. Baldwin, C. E., et al. 2004. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J. Virol. 78:12428-12437.
8. Beaumont, E., et al. 2009. Matrix and envelope coevolution revealed in a patient monitored since primary infection with human immunodeficiency virus type 1. J. Virol. 83:9875-9889.
9. Berro, R., R. W. Sanders, M. Lu, P. J. Klasse, and J. P. Moore. 2009. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog. 5:e1000548.
10. Binley, J. M., et al. 2003. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J. Virol. 77:5678-5684.
11. Binley, J. M., et al. 2000. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74:627-643.
12. Binley, J. M., et al. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252.
13. Bontjer, I., et al. 2009. Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J. Virol. 83:368-383.
14. Bosch, B. J., et al. 2004. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc. Natl. Acad. Sci. U. S. A. 101:8455-8460.
15. Caffrey, M. 2001. Model for the structure of the HIV gp41 ectodomain: insight into the intermolecular interactions of the gp41 loop. Biochim. Biophys. Acta 1536:116-122.
16. Cao, J., et al. 1993. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J. Virol. 67:2747-2755.
17. Chinnadurai, R., D. Rajan, J. Munch, and F. Kirchhoff. 2007. Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J. Virol. 81:6563-6572.
18. Das, A. T., B. Klaver, and B. Berkhout. 1999. A hairpin structure in the R region of the human immunodeficiency virus type 1 RNA genome is instrumental in polyadenylation site selection. J. Virol. 73:81-91.
19. Derdeyn, C. A., et al. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
20. Desmezieres, E., et al. 2005. Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120. J. Virol. 79:4774-4781.
21. Dwyer, J. J., et al. 2007. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. U. S. A. 104:12772-12777.
22. Eggink, D., et al. 2008. Selection of T1249-resistant human immunodeficiency virus type 1 variants. J. Virol. 82:6678-6688.
23. Eggink, D., B. Berkhout, and R. W. Sanders. 2010. Inhibition of HIV-1 by fusion inhibitors. Curr. Pharm. Des. 16:3716-3728.
24. Eggink, D., et al. 2009. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J. Biol. Chem. 284:26941-26950.
25. Eron, J. J., et al. 2004. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J. Infect. Dis. 189:1075-1083.
26. Finzi, A., et al. 2010. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol. Cell 37:656-667.
27. Gochin, M., and L. Cai. 2009. The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket. J. Med. Chem. 52:4338-4344.
28. Greenberg, A., et al. 2002. In vitro antiviral activity of T-1249 a second generation fusion inhibitor. Antivir. Ther. 7:S14.
29. Greenberg, A., et al. 2002. Enfuvirtide (T-20) and T-1249 resistance: observations from Phase II clinical trials of enfuvirtide in combination with oral antiretrovirals and a Phase I/II dose-ranging monotherapy trial of T-1249 Antivir. Ther. 7:S140.
30. He, Y., et al. 2007. Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J. Biol. Chem. 282:25631-25639.
31. He, Y., et al. 2008. Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition. J. Virol. 82:11129-11139.
32. He, Y., et al. 2008. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 283:11126-11134.
33. Helseth, E., U. Olshevsky, C. Furman, and J. Sodroski. 1991. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J. Virol. 65:2119-2123.
34. Huigen, M. C., et al. 2008. Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase. Retrovirology 5:20.
35. Jeeninga, R. E., W. Keulen, C. Boucher, R. W. Sanders, and B. Berkhout. 2001. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect. Virology 283:294-305.
36. Ji, H., W. Shu, F. T. Burling, S. Jiang, and M. Lu. 1999. Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J. Virol. 73:8578-8586.
37. Kim, S., H. B. Pang, and M. S. Kay. 2008. Peptide mimic of the HIV envelope gp120-gp41 interface. J. Mol. Biol. 376:786-797.
38. Lalezari, J. P., et al. 2005. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtidecontaining treatment regimen. J. Infect. Dis. 191:1155-1163.
39. Liu, S., et al. 2007. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J. Biol. Chem. 282:9612-9620.
40. Liu, Z., et al. 2011. In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 286:3277-3287.
41. Martins Do Canto, A. M., A. J. Palace Carvalho, J. P. Prates Ramalho, and L. M. Loura. 2008. T-20 and T-1249 HIV fusion inhibitors' structure and conformation in solution: a molecular dynamics study. J. Pept. Sci. 14:442-447.
42. Melby, T., R. Demasi, N. Cammack, G. D. Miralles, and M. L. Greenberg. 2007. Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249. AIDS Res. Hum. Retroviruses 23: 1366-1373.
43. Melby, T., et al. 2006. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res. Hum. Retroviruses 22:375-385.
44. Menzo, S., et al. 2004. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment. New Microbiol. 27:51-61.
45. Mink, M., et al. 2005. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 79:12447-12454.
46. Muster, T., et al. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
47. Naito, T., et al. 2009. SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob. Agents Chemother. 53:1013-1018.
48. Nameki, D., et al. 2005. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Revresponsive element functions. J. Virol. 79:764-770.
49. Nijhuis, M., et al. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349-2359.
50. Oishi, S., et al. 2009. Development of a novel fusion inhibitor against T-20-resistant HIV-1. Adv. Exp. Med. Biol. 611:389-391.
51. Oishi, S., et al. 2008. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity. J. Med. Chem. 51:388-391.
52. Ou, W., and J. Silver. 2005. Inhibition of murine leukemia virus envelope protein (env) processing by intracellular expression of the env N-terminal heptad repeat region. J. Virol. 79:4782-4792.
53. Peden, K., M. Emerman, and L. Montagnier. 1991. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 185: 661-672.
54. Porotto, M., et al. 2007. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. J. Virol. 81:10567-10574.
55. Ray, N., L. A. Blackburn, and R. W. Doms. 2009. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J. Virol. 83:2989-2995.
56. Ray, N., et al. 2007. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J. Virol. 81:3240-3250.
57. Rimsky, L. T., D. C. Shugars, and T. J. Matthews. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:986-993.
58. Sanders, R. W., E. Busser, J. P. Moore, M. Lu, and B. Berkhout. 2004. Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS Res. Hum. Retroviruses 20:742-749.
59. Shafer, R. W., and J. M. Schapiro. 2008. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 10: 67-84.
60. Sista, P. R., et al. 2004. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 18:1787-1794.
61. Sivaraman, V., L. Zhang, E. G. Meissner, J. L. Jeffrey, and L. Su. 2009. The heptad repeat 2 domain is a major determinant for enhanced human immunodeficiency virus type 1 (HIV-1) fusion and pathogenicity of a highly pathogenic HIV-1 Env. J. Virol. 83:11715-11725.
62. Su, C., T. Melby, R. DeMasi, P. Ravindran, and G. Heilek-Snyder. 2006. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. J. Clin. Virol. 36:249-257.
63. Svicher, V., et al. 2008. Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. J. Infect. Dis. 197:1408-1418.
64. Tolstrup, M., et al. 2007. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K). AIDS 21:519-521.
65. Trivedi, V. D., et al. 2003. The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20. Protein Eng. 16:311-317.
66. Wang, E., et al. 2003. Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion. Biochem. Biophys. Res. Commun. 302:469-475.
67. Wang, L. X., et al. 2005. Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34. Chembiochem 6:1068-1074.
68. Watabe, T., et al. 2009. X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitution. J. Mol. Biol. 392:657-665.
69. Wei, X., et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
70. Wild, C., T. Oas, C. McDanal, D. Bolognesi, and T. Matthews. 1992. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. U. S. A. 89:10537-10541.
71. Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A. 91:9770-9774.
72. Xu, L., et al. 2005. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob. Agents Chemother. 49:1113-1119.
73. Zhu, J., X. Jiang, Y. Liu, P. Tien, and G. F. Gao. 2005. Design and characterization of viral polypeptide inhibitors targeting Newcastle disease virus fusion. J. Mol. Biol. 354:601-613.